Recursion Pharmaceuticals
RXRX
126 hedge funds and large institutions have $1.62B invested in Recursion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 52 increasing their positions, 10 reducing their positions, and 11 closing their positions.
420% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 10
382% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 11
132% more call options, than puts
Call options by funds: $2.03M | Put options by funds: $878K
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
50% more funds holding
Funds holding: 84 → 126 (+42)
28% more capital invested
Capital invested by funds: $1.26B → $1.62B (+$352M)
24.61% more ownership
Funds ownership: 34.53% → 59.14% (+25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$94M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$64M |
| 3 |
State Street
Boston,
Massachusetts
|
+$56.7M |
| 4 |
AI
ArchPoint Investors
Coral Gables,
Florida
|
+$23.6M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$23.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CL
CRV LLC
Palo Alto,
California
|
-$16.9M |
| 2 |
Alkeon Capital Management
New York
|
-$12.6M |
| 3 |
YRHAM
Yong Rong (HK) Asset Management
Sheung Wan,
Hong Kong
|
-$8.68M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.09M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$6.81M |
RXRX Hedge Fund Activity: Q4 2021 in Review
126 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2021, worth a combined $1.62B — up 28% from $1.26B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new RXRX positions and 11 closed out — a net gain of 42 holders — while 52 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $94M. The largest seller was CRV LLC, exiting entirely with an estimated $16.9M sold.
- 126 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2021, up from 84 in Q3 2021.
- Funds reported $1.62B of Recursion Pharmaceuticals stock for Q4 2021, up 28% quarter-over-quarter.
- 53 funds opened new Recursion Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +42 holders.
- The largest Recursion Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $94M added.
- The largest Recursion Pharmaceuticals seller in Q4 2021 was CRV LLC, an estimated $16.9M sold.
Based on aggregated 13F filings for Q4 2021.